🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
NCT05246514HER2-mutant Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
72
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-07-13
Active, closed
INSPIRIS China PMCF Study
NCT05404880Aortic Valve Replacement
Edwards Lifesciences
Observational
255
Hefei, Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Xi’an
2022-07-13
Recruiting
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
NCT05487170Advanced Solid Tumor, DLBCL
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
32
Beijing
2022-07-12
Recruiting
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
NCT05165407Neuroendocrine Neoplasm
Peking University
Phase 2
30
Beijing
2022-07-12
Active, closed
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
NCT05460273Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer
AstraZeneca
Phase 1/2
119
Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-07-11
Recruiting
A Prospective Cohort Study on Colorectal Cancer Screening in Community Population
NCT05485077Colorectal Cancer
Singlera Genomics Inc.
Observational
18,000
Beijing
2022-07-09
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Daiichi Sankyo
Phase 3
586
Beijing, Changchun, Changsha, Chengdu, Chibi, Fuzhou, Guangzhou, Haidian
2022-07-08
Active, closed
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446Coronary Artery Disease
Novartis Pharmaceuticals
Phase 3
609
Beijing, Nanjing, Shanghai
2022-07-08
Active, closed
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT05226871Breast Cancer, Head and Neck Cancer
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Recruiting
Effects of CI on Tinnitus and Its Symptoms
NCT05453019Tinnitus
Chinese PLA General Hospital
Not applicable
200
Beijing
2022-07-04
Active, closed
Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT06196827Inherited Retinal Dystrophy Associated With RPE65 Mutations
Innostellar Biotherapeutics Co.,Ltd
Phase 1
9
Beijing, Shanghai
2022-07-02
Recruiting
Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma
NCT06644352Siewert Type II Adenocarcinoma of Esophagogastric Junction
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
236
Beijing
2022-07-01
Active, closed
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
NCT05383716Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
Peking Union Medical College Hospital
Phase 2
80
Beijing
2022-07-01
Recruiting
A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer
NCT06082180Thyroid Cancer, Recurrence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
1,199
Beijing
2022-07-01
Recruiting
Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
NCT05476627Chronic Kidney Diseases, Hypertension, Diabetes Mellitus, Hyperuricemia
Peking Union Medical College Hospital
Observational
200
Beijing
2022-07-01
Active, closed
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178HR-positive, HER2-negative Breast Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
432
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei, Guangzhou
2022-07-01
Recruiting
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
NCT05789030Autoimmune Diseases
Peking Union Medical College Hospital
Not applicable
60
Beijing
2022-07-01
Not yet open
Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China
NCT05451082Hepatitis D
Lai Wei
Observational
1,000
Beijing
2022-07
Active, closed
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
NCT05456425Pterygium
Cloudbreak Therapeutics, LLC
Phase 3
660
Beijing, Chengdu, Haikou, Hengyang, Kunming, Nanchang, Qingdao, Wenzhou
2022-06-30
Active, closed
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
NCT05364073Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations
ArriVent BioPharma, Inc.
Phase 1
160
Hefei, Beijing, Chaoyang, Chongqing, Harbin, Zhengzhou, Wuhan, Xuzhou
2022-06-30
Active, closed
TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration
NCT05461339Neovascular Age-related Macular Degeneration
BioDlink Biopharm Co., Ltd.
Phase 3
488
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Guangzhou, Shantou, Shenzhen
2022-06-28
Active, closed
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
NCT05319431Unresectable, Non-metastatic Hepatocellular Carcinoma
Akeso
Phase 2
60
Beijing, Guangzhou, Zhengzhou, Changsha, Jinan
2022-06-28
Active, closed
Observational Study in Multiple System Atrophy
NCT05453058Multiple System Atrophy
H. Lundbeck A/S
Observational
90
Beijing, Changsha, Chengdu, Shanghai, Suzhou
2022-06-25
Active, closed
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166Plasma Cell Myeloma Recurrent
Sanofi
Phase 3
531
Beijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanning, Qingdao, Shenyang
2022-06-23
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
Celgene
Phase 3
939
Changsha, Nanchang, Xi'an, Shanghai, Taiyuan, Wenzhou, Beijing, Changchun
2022-06-23
Active, closed
Clinical Trial to Evaluate MDW for Early Detection of Sepsis
NCT06267742Sepsis
Beckman Coulter, Inc.
Observational
2,200
Beijing, Chengdu, Hangzhou
2022-06-23
Recruiting
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
NCT05436093Solid Tumor
Peking University Cancer Hospital & Institute
Not applicable
50
Beijing
2022-06-23
Active, closed
Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma
NCT05464433Extranodal Natural Killer T Cell Lymphoma
Sun Yat-sen University
Phase 1/2
46
Beijing, Dalian, Guangzhou, Nanchang
2022-06-23
Recruiting
Deep Brain Stimulation for Idiopathic Craniofacial Dystonia: GPi or STN
NCT05416905Craniofacial Dystonia, Deep Brain Stimulation
Beijing Tiantan Hospital
Not applicable
110
Beijing
2022-06-22
Active, closed
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
NCT05235516Locally Advanced Cervical Carcinoma
Akeso
Phase 3
636
Beijing, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2022-06-21
Recruiting
A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)
NCT05603078Breast Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
102
Beijing
2022-06-21
Recruiting
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
NCT05773937Advanced Malignant Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
40
Beijing
2022-06-21
Active, closed
Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer
NCT05444491Colorectal Cancer
Singlera Genomics Inc.
Observational
800
Beijing, Chengdu, Guangzhou, Haerbin, Shanghai, Shenzhen, Taiyuan
2022-06-20
Not yet open
The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer
NCT05411809Stereotactic Body Radiation Therapy
Peking University Third Hospital
Not applicable
180
Beijing
2022-06-15
Recruiting
The Effectiveness of Written Exposure Therapy for PTSD
NCT05421494PTSD, Subclinical PTSD
Peking University
Not applicable
135
Beijing
2022-06-15
Active, closed
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
NCT05132075Non-Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 3
95
Fuzhou, Guangzhou, Harbin, Changsha, Shengyang, Jinan, Hangzhou, Beijing
2022-06-15
Active, closed
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
NCT05047250Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3
60
Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing
2022-06-14
Active, closed
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05283720Non-Hodgkin Lymphoma
Genmab
Phase 2
264
Beijing, Shanghai
2022-06-14
Recruiting
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
NCT05302284Urothelial Carcinoma, HER2-expressing
RemeGen Co., Ltd.
Phase 3
452
Beijing
2022-06-14
By invitation
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT05352919Systemic Lupus Erythematosus (SLE)
Biogen
Phase 3
864
Beijing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Haikou, Shijiazhuang, Changsha
2022-06-10
Active, closed
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
NCT05347134Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
254
Beijing, Nanjing
2022-06-10
Recruiting
Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy
NCT05341141Breast Cancer
Peking University
Not applicable
102
Beijing
2022-06-10
Recruiting
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
NCT06998108HR+/HER2- Locally Advanced, Metastatic Breast Cancer
BeBetter Med Inc
Phase 3
330
Beijing
2022-06-09
Active, closed
The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.
NCT05797714HBV Infection, Chronic Hepatitis b
Ruijin Hospital
Not applicable
200
Changsha, Beijing, Dongyang, Fuyang, Hangzhou, Lishui, Nanchang, Nanjin
2022-06-08
Recruiting
A Study of ASP3082 in Adults With Advanced Solid Tumors
NCT05382559Solid Tumor
Astellas Pharma Inc
Phase 1
681
Beijing, Xuhui District, Shanghai
2022-06-08
Active, closed
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT05294172Nasopharyngeal Carcinoma, Recurrent or Metastatic
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
295
Beijing
2022-06-07
Recruiting
Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis
NCT05288179Pneumoconiosis
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3
272
Beijing
2022-06-07
Active, closed
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
NCT05195632Non-Small Cell Lung Cancer
Pierre Fabre Medicament
Phase 2
63
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-06-02
Not yet open
Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics
NCT05369689Stereotactic Radiosurgery, Spinal Tumor, Radiomics, Prognosis
Zhuang Hongqing
Observational
300
Beijing
2022-06-01
Recruiting
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
NCT05566002Pulmonary Hypertension, Pulmonary Arterial Hypertension
Chinese Pulmonary Vascular Disease Research Group
Observational
2,000
Beijing
2022-06-01
Recruiting
General Anesthetics-related Changes in Prefrontal EEG During Pediatric Surgical Anesthesia
NCT05210764General Anesthetic, Electroencephalogram
Peking University First Hospital
Observational
366
Beijing
2022-06-01
Active, closed
Intracranial Arterial Stenosis in Young Patients
NCT05844176Intracranial Arterial Stenosis
Capital Medical University
Observational
500
Suzhou, Shijiazhuang, Beijing, Zhengzhou
2022-06-01
Recruiting
A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
NCT05217693Solid Tumor
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Phase 1
288
Beijing, Changsha, Ganzhou, Hangzhou, Hanzhou, Linyi, Nanjing
2022-06-01
Not yet open
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
NCT05431504Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
53
Beijing
2022-06
Not yet open
Cohort Study of Patients With Type 1 Diabetes Registered With Mobile Application in China
NCT05163054Type 1 Diabetes
Peking University Third Hospital
Observational
500
Beijing
2022-06
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
Dimerix Bioscience Pty Ltd
Phase 3
286
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Hohhot, Jinan, Nanchang
2022-05-30
Recruiting
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
NCT05315167Advanced Solid Tumor, Advanced Solid Malignancies
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1/2
267
Zhengzhou, Chengdu, Hangzhou, Beijing
2022-05-30
Active, closed
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
CStone Pharmaceuticals
Phase 2
70
Guangzhou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2022-05-27
Active, closed
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
NCT05879068SCLC
Biotheus Inc.
Phase 2
99
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nanchang
2022-05-27
Recruiting
Evaluation of Clinical Outcomes of Unruptured bAVMs Treated With Medical Management Alone Based on Multimodal CT
NCT05449106Brain Arteriovenous Malformations
Beijing Tiantan Hospital
Observational
200
Beijing, Zhengzhou, Nanjing
2022-05-25
Recruiting
A Prognostic Model for Drug-induced Liver Injury in China
NCT05060289Drug-induced Liver Injury
Beijing Friendship Hospital
Observational
3,000
Beijing, Dalian, Guangxi, Hebei, Jiaozuo, Lanzhou, Qingdao, Qinghai
2022-05-25
Recruiting
ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy
NCT05392699Patients With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
60
Beijing
2022-05-25
Recruiting
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
NCT05430373Solid Tumors, Adult
Grit Biotechnology
Phase 1
31
Beijing, Chongqing, Shanghai, Chengdu, Tianjin
2022-05-23
Active, closed
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257Limited-Stage Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 3
511
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guilin
2022-05-17
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
AstraZeneca
Phase 3
644
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-05-16
Active, closed
Clinical Study of NovoClasp for Treating Moderate to Severe and Severe Degenerative Mitral Regurgitation
NCT06021509Degenerative Mitral Valve Disease
Enlight Medical Technologies (Shanghai) Co., Ltd
Not applicable
102
Beijing
2022-05-15
Recruiting
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
NCT05498064Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase I1171N, Ensartinib
Peking Union Medical College Hospital
Observational
490
Beijing
2022-05-13
Recruiting
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705Breast Cancer
Eli Lilly and Company
Phase 1
260
Beijing, Nanchang, Shanghai
2022-05-11
Recruiting
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
NCT07400224Hyperthyroidism, Autoimmune, Cardiovascular Abnormalities, Malignant Tumor
Peking Union Medical College Hospital
Phase 1/2
600
Beijing
2022-05-10
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
NCT05294731B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BeiGene
Phase 1/2
146
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Nanyang
2022-05-06
Recruiting
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
NCT05090891Fibrodysplasia Ossificans Progressiva (FOP)
Incyte Corporation
Phase 2
98
Beijing, Shanghai
2022-05-05
Recruiting
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
NCT05179876Hypertension, Pulmonary
Actelion
Phase 3
280
Beijing, Changsha, Nanjing, Qingdao, Shanghai, Xi'an
2022-05-04
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT05280548Fabry Disease
Sanofi
Phase 3
104
Beijing, Chengdu, Guangzhou, Shanghai
2022-05-03
Recruiting
Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
NCT05332756Moyamoya Disease
Beijing Tiantan Hospital
Observational
400
Beijing
2022-05-01
Recruiting
Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
NCT05349552Radiotherapy, Thoracic Cancer, Safety and Efficacy
Peking University Third Hospital
Observational
120
Beijing
2022-05-01
Recruiting
Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
NCT05189054Stereotactic Body Radiation Therapy, Irradiation; Reaction, Thoracic Tumor, Recurrent Cancer
Peking University Third Hospital
Observational
40
Beijing
2022-05-01
Recruiting
Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
NCT06417502Autoimmune Diseases, Autoinflammatory Diseases
Peking Union Medical College Hospital
Observational
20,000
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Hangzhou
2022-04-29
Recruiting
Acupuncture vs Sham Acupuncture for Hand Osteoarthritis
NCT05267093Hand Osteoarthritis
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
340
Beijing
2022-04-26
Recruiting
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
NCT05294055Multiple Myeloma, Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Active, closed
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
Shanghai Henlius Biotech
Phase 3
900
Bengbu, Hefei, Lu'an, Ma’anshan, Wuhu, Beijing, Chongqing, Chongqi
2022-04-25
Recruiting
Super-Hypofractionated Partial Breast Irradiation
NCT06615466Breast Cancer, Radiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2022-04-22
Recruiting
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
NCT05248633Solitary Plasmacytoma
Peking Union Medical College Hospital
Phase 2
220
Beijing
2022-04-21
Recruiting
Multiomics Tumor Evolution Model of NSCLC
NCT05352035Non-small Cell Lung Cancer
Peking University People's Hospital
Observational
300
Beijing
2022-04-20
By invitation
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
NCT05303532Cancer
AstraZeneca
Phase 3
214
Beijing, Changsha, Hangzhou, Nanjing, Shanghai, Shenyang, Wenzhou, Xi'an
2022-04-19
Active, closed
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
NCT05222906Gaucher's Disease Type III
Sanofi
Phase 3
43
Taipei, Beijing, Guangzhou, Shanghai
2022-04-18
Recruiting
BeijngFH Health Cohort Study
NCT05546086Non-Alcoholic Fatty Liver Disease
Beijing Friendship Hospital
Observational
8,103
Beijing
2022-04-18
Active, closed
A Study of Anti-IL-6R mAb Injection in Patients With iMCD
NCT05345522Idiopathic Multicentric Castleman's Disease
Beijing VDJBio Co., LTD.
Phase 2
25
Beijing, Chengdu
2022-04-18
Recruiting
China Gender-affirming Hormone Therapy Study
NCT05318755Transgender, Gender Incongruence
Peking University Third Hospital
Observational
240
Beijing
2022-04-16
Recruiting
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
NCT05324332Prostate Cancer
Peking Union Medical College Hospital
Not applicable
50
Beijing
2022-04-15
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Active, closed
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
Eli Lilly and Company
Phase 3
925
Bengbu, Hefei, Wuhu, Beijing, Guangzhou, Harbin, Wuhan, Changsha
2022-04-14
By invitation
Study of Brain Function Evaluation and Intervention System for Acute and Prolonged Disorders of Consciousness
NCT05682248Disorder of Consciousness
Xuanwu Hospital, Beijing
Not applicable
180
Beijing
2022-04-13
By invitation
Study of Brain Function Evaluation System for Acute and Prolonged Disorders of Consciousness
NCT06097013Disorder of Consciousness
Xuanwu Hospital, Beijing
Observational
500
Beijing
2022-04-13
Recruiting
Modified CV Regimen in Optic Pathway Glioma
NCT05278715Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma
Beijing Sanbo Brain Hospital
Phase 2
75
Beijing
2022-04-13
Recruiting
Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
NCT05327517Cervical Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
192
Beijing
2022-04-10
Active, closed
An Observational Cohort Study to Obese Patients With Weight Cycling
NCT05311462Weight Cycling, Obesity
Peking Union Medical College Hospital
Observational
180
Beijing
2022-04-08
Recruiting
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
NCT05427383Stomach Cancer
Shanghai JMT-Bio Inc.
Phase 2/3
286
Beijing
2022-04-07
Recruiting
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
NCT05145361NMO Spectrum Disorder
Shanghai Pharmaceuticals Holding Co., Ltd
Phase EARLY_PHASE1
45
Beijing, Taiyuan, Xi’an, Tianjin
2022-04-07
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Beijing, Guangzhou, Changsha, Wuxi, Nanchang, Jinan, Chengdu, Yibin
2022-04-05
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT05239741Colorectal Neoplasms
Merck Sharp & Dohme LLC
Phase 3
100
Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin
2022-04-02
Rows per page Showing 4601–4700 of 5484
Previous 45 46 47 48 49 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=47

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.